TCRT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:14):

Stats
Today's Volume	1 421.00
Average Volume	93 895.00
Market Cap	18.81M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-0.450 ) 2024-06-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0290 (2.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Groenewald Ferdinand	Buy	0
2024-01-20	Hogue Dale Curtis Jr.	Buy	600 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	150 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	41 667	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	0

INSIDER POWER
96.80
Last 87 transactions
Buy: 16 191 500 \| Sell: 2 243 866

Alaunos Therapeutics, Correlation

10 Most Positive Correlations
WISA	0.942
ALZN	0.935
TTCF	0.935
KVSB	0.932
ALLO	0.931
GH	0.927
ADSE	0.926
AGFY	0.925
COMT	0.925
INFI	0.924

10 Most Negative Correlations
IBEX	-0.937
ISIG	-0.92
STAY	-0.914
RNLC	-0.913
CCRC	-0.912
SLGN	-0.91
USLB	-0.904
SEDG	-0.903
XOMAO	-0.903
VLYPO	-0.894

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alaunos Therapeutics, Financials

Annual	2023
Revenue:	$5 000.00
Gross Profit:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

Q4	2023
Revenue:	$1 000.00
Gross Profit:	$-240 000 (-24 000.00 %)
EPS:	$-0.490

Q3	2023
Revenue:	$0
Gross Profit:	$-1.06M (0.00 %)
EPS:	$-0.530

Q2	2023
Revenue:	$4 000.00
Gross Profit:	$-1.53M (-38 225.00 %)
EPS:	$-0.550

Financial Reports:

No articles found.

Alaunos Therapeutics,

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.